FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Simulations Cut Generic Drug Development: FDA

FDA generic drug researchers say modeling can shorten development time for generic drug-device combination drugs.

Human Drugs

CGMP Violations at Koreas Celltrion

FDA warns Koreas Celltrion about CGMP violations in its production of finished pharmaceuticals.

Human Drugs

Polaroisin International CGMP Violations

FDA warns Taiwans Polaroison International about CGMP violations in its production of finished pharmaceuticals.

Human Drugs

FDA Sets Generic Drug Research Workshop

FDA announces a 4/24 public workshop on the current status of the regulatory science initiatives for generic drugs.

FDA Gives Octo $300 Million Approval Process Contract

FDA chooses Octo Consulting for a seven-year contract to modernize and streamline the drug and medical device approval process as required by the 21st...

FDA General

Revise Clinical Decision Support Guidance: Coalition

Two stakeholders recommend changes to an FDA draft guidance on clinical decision support software.

Human Drugs

New FDA Research on Kratom Opioid Properties

FDA commissioner Scott Gottlieb says agency scientists have found new data confirming opioid properties and 44 deaths reported from use of abusable bo...

Human Drugs

Guidance Helps Generics Industry Submit Better Apps

A CDER small business podcast says generic drug manufacturers can find ANDA submission help in a recent guidance aiming to reduce the number of review...

Human Drugs

Form 483 Cites Repeat Observation at Outsourcing Facility

FDA posts a Form 483 from a 1/24-completed inspection of Houston, TX-based Empower Pharmacy that cites a repeat observation from an earlier inspection...

Federal Register

Percutaneous Nerve Stimulator for Substance Disorder in Class 2

Federal Register notice: FDA classifies the percutaneous nerve stimulator for substance use disorders into Class 2 (special controls).